Can you take GOLO after gastric sleeve surgery? It is a question many post-bariatric patients ask as they seek to optimise their weight loss journey. GOLO is a US-originated weight management programme combining a structured diet with a proprietary supplement called Release, which contains berberine, chromium, magnesium, zinc, and herbal extracts. While the dietary principles broadly align with NHS guidance, the supplement component raises important safety considerations for sleeve gastrectomy patients, whose altered anatomy, nutritional needs, and medication regimens demand careful clinical oversight before introducing any new product.

What Is GOLO and How Does It Work?

GOLO combines a whole-food dietary plan with the Release supplement, which contains berberine, chromium, and herbal extracts marketed to improve insulin sensitivity. It is a food supplement, not an MHRA-licensed medicine, and has not been formally evaluated by NICE or MHRA.

GOLO is a commercially available weight management programme originating in the United States. It combines a structured dietary plan with a proprietary supplement called Release, which contains a blend of plant-based extracts and minerals. Ingredients listed on the product label typically include magnesium, zinc, chromium, berberine, Rhodiola rosea extract, Inositol, and Banaba leaf extract, though the exact formulation and doses per capsule may vary between markets and batches. This variability is an important consideration when assessing safety.

The programme is marketed around the concept of improving insulin sensitivity and stabilising blood glucose levels to support weight loss. Some individual ingredients — particularly chromium and berberine — have been studied in the context of blood glucose regulation, though the quality of this evidence is variable and largely based on small trials. No high-quality randomised controlled trials specifically evaluating the GOLO programme in post-bariatric adults have been identified in the published literature.

It is important to understand the UK regulatory context. GOLO Release is marketed as a food supplement, not an MHRA-licensed medicine. It is not covered by the MHRA Traditional Herbal Registration (THR) scheme, and neither the MHRA nor NICE has formally evaluated or endorsed it as a weight management intervention. Food supplements in the UK are regulated by the Food Standards Agency (FSA) and are not subject to the same pre-market safety and efficacy assessments as licensed medicines. Quality, purity, and dose consistency may therefore vary between manufacturers and batches, and consumers should purchase from reputable, established suppliers.

The dietary component of the GOLO plan — which emphasises whole foods, reduced processed sugar, and calorie moderation — broadly aligns with the principles of the NHS Eatwell Guide. However, the supplement component raises specific considerations for individuals who have undergone bariatric surgery, particularly gastric sleeve (sleeve gastrectomy), where absorption, tolerability, and nutritional status are fundamentally altered.

If you experience any suspected side effects from a food supplement or herbal product, you can report these to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

Nutritional Considerations After Gastric Sleeve Surgery

Sleeve gastrectomy removes 75–80% of the stomach, significantly increasing the risk of deficiencies in iron, vitamin B12, vitamin D, calcium, zinc, and magnesium that require lifelong monitoring and prescribed supplementation. Adding unsupervised supplements risks dangerous nutrient imbalances.

Sleeve gastrectomy involves the surgical removal of approximately 75–80% of the stomach, creating a narrow, tube-shaped gastric remnant. This significantly reduces food intake capacity and alters the digestive process. As a result, individuals who have undergone this procedure face a substantially increased risk of nutritional deficiencies, which require careful, lifelong management.

Common deficiencies following gastric sleeve surgery include:

• Iron — particularly in premenopausal women

• Vitamin B12 — due to reduced intrinsic factor production

• Vitamin D and calcium — affecting bone health

• Folate and thiamine (vitamin B1) — especially in those with poor dietary variety or persistent vomiting

• Zinc and magnesium — which can become depleted and require monitoring

In line with guidance from the British Obesity and Metabolic Surgery Society (BOMSS), post-bariatric patients should undergo scheduled blood tests to monitor nutritional status — typically at 3, 6, and 12 months post-operatively, and annually thereafter. Standard lifelong supplementation following sleeve gastrectomy typically includes a bariatric-formulated multivitamin and mineral supplement, vitamin D, calcium citrate, and vitamin B12, as directed by the surgical team. Patients should not adjust or supplement beyond their prescribed regimen without specialist advice.

A particular urgent red flag is persistent vomiting or an inability to keep fluids down. This can rapidly deplete thiamine (vitamin B1) and, if untreated, may lead to serious neurological complications such as Wernicke's encephalopathy. If you experience persistent vomiting after surgery, seek urgent medical attention. Clinicians should ensure thiamine is administered before any glucose-containing fluids in this context.

Introducing additional supplements — such as those contained within the GOLO Release capsule — without professional guidance risks creating nutrient imbalances, particularly with minerals such as zinc and magnesium, which are already included in standard post-bariatric regimens. Exceeding recommended intakes of these minerals can itself cause harm.

Tolerability is also a practical concern. Capsules or tablets that are well tolerated in the general population may cause nausea, discomfort, or gastrointestinal symptoms in post-sleeve patients. Extended-release or enteric-coated formulations should generally be avoided in the early post-operative period due to unpredictable absorption. Any new supplement should be introduced cautiously and only after discussion with a qualified healthcare professional familiar with the patient's post-operative status. The NHS Weight Loss Surgery aftercare pages provide further patient-facing guidance on long-term supplementation and follow-up.

Supplement and Medication Interactions After Gastric Sleeve

Berberine in GOLO Release inhibits CYP3A4 and lowers blood glucose, risking hypoglycaemia and raised plasma levels of narrow-therapeutic-index drugs including DOACs, ciclosporin, and digoxin. Medical review is essential before use.

One of the most clinically significant concerns when considering any new supplement after gastric sleeve surgery is the potential for interactions with existing medications or prescribed supplements. Many post-bariatric patients are on long-term medications for conditions such as type 2 diabetes, hypertension, or thyroid disorders, and the altered gastrointestinal anatomy can affect how these drugs are absorbed and metabolised.

The GOLO Release supplement contains berberine, a compound with known glucose-lowering properties. Berberine has been shown in studies to reduce blood glucose levels through mechanisms that include activation of AMP-activated protein kinase (AMPK), with effects broadly comparable to metformin. For individuals already taking antidiabetic medications — including metformin, insulin, sulphonylureas, or GLP-1 receptor agonists — adding berberine without medical supervision could increase the risk of hypoglycaemia (abnormally low blood sugar). This is particularly important given that blood glucose levels often improve significantly following bariatric surgery, sometimes necessitating dose reductions in existing diabetes medications. People taking insulin, sulphonylureas, or GLP-1 receptor agonists should increase self-monitoring of blood glucose and arrange a prompt medication review with their GP or diabetes team before starting any supplement with glucose-lowering properties.

Berberine is also a known inhibitor of CYP3A4 and P-glycoprotein, metabolic pathways involved in the processing of many medicines. This means it may raise plasma levels of drugs with a narrow therapeutic index, including ciclosporin, tacrolimus, certain direct oral anticoagulants (DOACs), and digoxin. Patients taking any of these medicines should seek specialist review before considering berberine-containing products.

Regarding chromium: the BNF and product guidance for levothyroxine advise separating mineral supplements from thyroid medication doses to avoid potential absorption interference. If you take levothyroxine, discuss the timing of any mineral-containing supplement with your pharmacist or GP. Claims that chromium directly interacts with thyroid medication pharmacology are not well established, and patients should seek individual advice rather than assuming a significant interaction.

The herbal ingredient Rhodiola rosea has been associated with mild stimulant-like effects. There is limited and largely theoretical evidence suggesting a potential interaction with serotonergic antidepressants (such as SSRIs or SNRIs). Until more robust evidence is available, it is advisable to avoid combining Rhodiola-containing products with serotonergic medicines unless under medical supervision.

The altered gastric pH and reduced transit time following sleeve gastrectomy can affect the bioavailability of supplement ingredients unpredictably, meaning that standard dosing guidance on product labels may not apply to post-bariatric patients. The MHRA advises caution with herbal products that have not undergone formal licensing review, as quality, purity, and dosage consistency can vary.

Additional cautions: these supplements have not been evaluated for safety in pregnancy or breastfeeding and should be avoided in these circumstances. Caution is also warranted in individuals with liver disease. Stop taking any supplement and seek medical advice promptly if you develop jaundice, dark urine, or severe itching, as these may indicate liver toxicity.

Suspected adverse reactions to supplements or herbal products should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

NHS and NICE Guidance on Post-Bariatric Weight Management

NICE and BOMSS recommend long-term specialist MDT follow-up after bariatric surgery, with weight management supported through evidence-based diet, physical activity, and behavioural support. NICE does not endorse commercial supplement programmes such as GOLO in post-bariatric care pathways.

NICE guidance on obesity management (CG189: Obesity: identification, assessment and management, and its associated updates) and NICE Quality Standard QS127 provide a clear framework for supporting patients after weight loss surgery. The NHS recommends that individuals who have undergone bariatric procedures receive long-term follow-up from a specialist multidisciplinary team (MDT), which typically includes a bariatric surgeon, dietitian, specialist nurse, and psychological support where appropriate. BOMSS guidance further defines the responsibilities of both specialist and primary care teams in providing structured monitoring and supplementation support after surgery.

In terms of post-operative nutrition, NICE, NHS bariatric services, and BOMSS all emphasise the importance of evidence-based dietary progression — moving from fluids to puréed foods, soft foods, and eventually a balanced solid diet — alongside lifelong adherence to prescribed vitamin and mineral supplementation. Weight management after surgery is expected to be supported through dietary counselling, physical activity, and behavioural support rather than through additional commercial weight loss products.

NICE does not currently recommend or endorse any commercial supplement programmes, including GOLO, as part of post-bariatric care pathways. The guidance stresses that any pharmacological or supplementary intervention introduced after surgery should be reviewed by the patient's bariatric team to ensure it is appropriate, safe, and does not interfere with ongoing nutritional rehabilitation.

For patients who experience weight regain after gastric sleeve surgery — which can occur in a proportion of individuals over time — NICE guidance supports referral back to the bariatric MDT for reassessment. Options may include dietary review, psychological support, or in some cases consideration of revision surgery or adjunctive pharmacotherapy. NICE Technology Appraisal TA875 (semaglutide 2.4 mg for weight management) sets out the criteria under which this treatment may be considered within specialist NHS weight management services. Any anti-obesity pharmacotherapy should be initiated in line with the relevant NICE technology appraisal and within eligible specialist services, rather than through self-directed supplementation.

The NHS Weight Loss Surgery aftercare pages provide accessible patient-facing information on long-term follow-up, supplementation, and when to seek help.

When to Speak to Your Bariatric Team Before Trying New Supplements

Consult your bariatric team before starting GOLO or any supplement after gastric sleeve surgery to assess ingredient interactions, medication risks, and nutritional suitability. Seek urgent care if you experience persistent vomiting, hypoglycaemia, or neurological symptoms.

If you are considering taking GOLO or any other commercial supplement programme following gastric sleeve surgery, the most important first step is to consult your bariatric team before starting. This is not merely a precaution — it is an essential part of safe post-operative care. Your bariatric dietitian or surgeon can review the full ingredient list of any proposed supplement, assess potential interactions with your current medications and prescribed vitamins, and advise on whether the product is appropriate for your individual circumstances.

You should seek prompt advice from your bariatric team or GP if you experience any of the following after starting a new supplement:

• Nausea, vomiting, or abdominal discomfort that is new or worsening

• Symptoms of hypoglycaemia, such as shakiness, sweating, confusion, or palpitations — particularly if you take diabetes medicines

• Unusual fatigue, dizziness, or neurological symptoms, which may indicate a nutritional imbalance

• Changes in bowel habit or symptoms suggestive of dumping syndrome

• Any new or unexplained symptoms that coincide with starting the supplement

Seek urgent medical attention or contact NHS 111 if you experience persistent vomiting or are unable to keep fluids down for more than 24 hours, severe abdominal pain, fever, or any neurological symptoms such as confusion, visual disturbance, or difficulty with coordination. These may indicate serious complications including thiamine deficiency, and require prompt assessment.

If you take insulin, a sulphonylurea, or a GLP-1 receptor agonist, increase your blood glucose self-monitoring and arrange a medication review before starting any supplement with potential glucose-lowering effects. Stop the supplement and seek medical advice if you experience hypoglycaemic episodes.

Always inform your GP and any other treating clinicians of all supplements you are taking, as this is relevant to your overall medication review and blood test interpretation. Biotin (vitamin B7), for example, is a well-recognised cause of interference with immunoassay-based laboratory tests, and clinicians should be aware of all supplements when interpreting results.

Suspected side effects from any supplement or herbal product can be reported to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

Ultimately, the desire to optimise weight loss outcomes after bariatric surgery is entirely understandable, and many patients seek additional tools to support their progress. However, the post-sleeve period is a time of significant physiological change, and the safest and most effective approach to long-term weight management remains one that is guided by your specialist team, grounded in evidence-based nutrition, and tailored to your individual health needs. Commercial supplement programmes are not a substitute for this personalised, clinically supervised care.

Frequently Asked Questions